Apricus Biosciences Inc. (APRI) and Stellar Pharmaceuticals Inc. (SLXCF.OB, SLXCF.OB, SLXCF.PK), announced the signing of an exclusive license agreement.
As per the agreement, Stellar Pharma has the exclusive right to sell Apricus Bio's MycoVa product for the treatment of onychomycosis (nail fungus) in Canada, following receipt of Canadian regulatory approval for such product.
The exclusive license agreement provides for an upfront payment, regulatory approval milestone, sales achievement milestones and royalty payments during the term of the agreement.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.